Advertisement

Malignant Melanoma

Current Status of the Search for Melanoma-Specific Antigens
  • Alan N. Houghton
  • Herbert F. Oettgen
  • Lloyd J. Old
Part of the Comprehensive Immunology book series (COMIMUN, volume 7)

Abstract

Malignant melanoma has a reputation as one of the most capricious and aggressive human cancers. The incidence and mortality have been rising in developed countries at a rate exceeding that of all other cancers except lung cancer (Lee and Carter, 1970). At present, in the United States, 10,000 individuals develop cutaneous malignant melanoma each year, an incidence slightly higher than that of Hodgkin’s disease (Levin and Baranovsky, 1976). Despite its reputation, the overall survival from melanoma is better than that from most common solid tumors, with approximately 70% of patients surviving at 5 years. When metastases are not evident, i.e., stage I melanoma, 85% of patients survive 5 years or more with treatment. However, once melanoma has metastasized, more than two-thirds of patients will die from their disease. These advanced stages of disease have been particularly resistant to conventional treatments; therapy of metastatic melanoma remains at this time generally unsatisfactory.

Keywords

Melanoma Cell Melanoma Cell Line Cell Surface Antigen Melanoma Antigen Melanoma Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahuja, M. R., and Anders, F., 1977, Cancer as a problem of gene regulation, Recent Adv. Cancer Res. 1: 103–117.Google Scholar
  2. Allen, E. P., 1955, Malignant melanoma—spontaneous regression after pregnancy, Br. Med. J. 2: 1067.PubMedCrossRefGoogle Scholar
  3. Anders, A., and Anders, F., 1978, Etiology of cancer as studied in the platyfish-swordtail system, Biochim. Biophys. Acta 516: 61–95.PubMedGoogle Scholar
  4. Anderson, D. E., 1971, Clinical characteristics of the genetic variety of cutaneous melanoma in man, Cancer 28: 721–725.PubMedCrossRefGoogle Scholar
  5. Axler, D. A., and Girardi, A. J., 1970, SV40 tumor-specific transplantation antigen (TSTA) in NDV lysates of SV40 transformed cells, Proc. Am. Assoc. Cancer Res. 11: 4–10.Google Scholar
  6. Bergholtz, B., Brennhovd, I., Klepp, O., Kaakinen, A., and Thorsby, E., 1977, HLA antigens in malignant melanoma, Cancer 39: 2342–2344.PubMedCrossRefGoogle Scholar
  7. Birdwell, C. R., Gospodarowicz, D., and Nicolson, G. L., 1978, Identification, localization, and role of fibronectin in cultured bovine endothelial cells, Proc. Natl. Acad. Sci. USA 75: 3273–3277.PubMedCrossRefGoogle Scholar
  8. Bodurtha, A. J., Berkelhamner, J., Kim, Y. H., Laucius, J. P., and Mastrangelo, M. J., 1976, A clinical, histologic and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission, Cancer 37: 735–742.PubMedCrossRefGoogle Scholar
  9. Boone, C. W., Paranjpe, M., Orme, T., and Gillette, R., 1974, Virus-augmented tumor transplantation antigens: Evidence for a helper antigen mechanism, Int. J. Cancer 13: 543–551.PubMedCrossRefGoogle Scholar
  10. Boone, C. W., Austin, F. C., Gail, M., Case, R., and Klein, E., 1978, Melanoma skin test antigens of improved sensitivity prepared from vesicular stomatitis virus-infected tumor cells, Cancer 41: 1781–1787.PubMedCrossRefGoogle Scholar
  11. Carey, T. E., Takahashi, T., Resnick, L. A., Oettgen, H. F., and Old, L. J., 1976, Cell surface antigens of human malignant melanoma. I. Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells, Proc. Natl. Acad. Sci. USA 73: 3278–3282.PubMedCrossRefGoogle Scholar
  12. Carey, T. E., Lloyd, K. O., Takahashi, T., Travassos, L. R., and Old, L. J., 1979, AU cell-surface antigen of human malignant melanoma: Solubilization and partial characterization, Proc. Natl. Acad. Sci. USA 76: 2898–2902.PubMedCrossRefGoogle Scholar
  13. Clark, D. A., Necheles, T., Nathanson, L., and Silverman, E., 1972, Apparent HL-A5 deficiency in malignant melanoma, Transplantation 15: 326–328.CrossRefGoogle Scholar
  14. Clark, W. H., From, L., Bernardino, E. A., and Mihm, M. C., 1969, The histogenesis and biologic behavior of primary human malignant melanoma of the skin, Cancer Res. 29: 705–727.PubMedGoogle Scholar
  15. Clark, W. H., Mastrangelo, M. J., Ainsworth, A. M., Berd, D., Bellet, R. E., and Bernardino, 1977, Current concepts of the biology of human cutaneous malignant melanoma, Adv. Cancer Res. 24: 267–338.PubMedCrossRefGoogle Scholar
  16. DeLeo, A. B., Shiku, H., Takahashi, T., John, M., and Old, L. J., 1977, Cell surface antigens of chemically induced sarcomas of the mouse. I. MuLV-related antigens and alloantigens on cultured fibroblasts and sarcoma cells. Description of a unique antigen on transplanted Meth A sarcoma, J. Exp. Med. 146: 720–734.PubMedCrossRefGoogle Scholar
  17. DeLeo, A. B., Shiku, H., Takahashi, T., and Old, L. J., 1978, Serological definition of cell surface antigens of chemically induced sarcomas of inbred mice, in: Biological Markers of Neoplasia: Basic and Applied Aspects (R. W. Ruddon, ed.), pp. 25–34, Elsevier/NorthHolland, New York.Google Scholar
  18. DeLeo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W., and Old, L. J., 1979, Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse, Proc. Natl. Acad. Sci. USA 76: 2420–2424.PubMedCrossRefGoogle Scholar
  19. Environmental Impact of Stratospheric Flight,1975, National Academy of Sciences, Washington, D.C.Google Scholar
  20. Everson, T. C., 1964, Spontaneous regression of cancer, Ann. N.Y. Acad. Sci. 114: 721.CrossRefGoogle Scholar
  21. Ferrone, S., and Pellegrino, M. A., 1979, Serological detection of human melanoma-associated antigens, in: Immunodiagnosis of Cancer ( R. Herberman and K. R. McIntyre, eds.), pp. 588–632, Dekker, New York.Google Scholar
  22. Fiori, M., and diMayorca, G., 1976, Occurrence of BK virus DNA in DNA obtained from certain human tumors, Proc. Natl. Acad. Sci. USA. 73: 4662–4666.PubMedCrossRefGoogle Scholar
  23. Foley, E. J., 1953, Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin, Cancer Res. 13: 835–837.PubMedGoogle Scholar
  24. Fraumeni, J. F., and Hoover, R., 1975, Immunosurveillance and Cancer: Epidemiologic Observations, NCI Monograph 47, pp. 121–126, U.S. Department of Health, Education, and Welfare, Washington, D.C.Google Scholar
  25. Galfré, G., Howe, S. C., Milstein, C., Butcher, G. W., and Howard, J. C., 1977, Antibodies to major histocompatible antigens produced by hybrid cell lines, Nature (London) 266: 550–552.CrossRefGoogle Scholar
  26. Garrett, T. J., Takahashi, T., Clarkson, B. D., and Old, L. J., 1977, Detection of antibody to autologous human leukemia cells by immune adherence assay, Proc. Natl. Acad. Sci. USA 74: 4578–4590.CrossRefGoogle Scholar
  27. Germain, R. N., Dorf, M. E., and Benacerraf, B., 1975, Inhibition of T-lymphocyte mediated tumor specific lysis by alloantisera directed against the H-2 serological specificities of the tumor, J. Exp. Med. 142: 1023–1028.PubMedCrossRefGoogle Scholar
  28. Gillis, S., Baker, P.E., Ruscetti, F. W., and Smith, K. A., 1978, Long-term culture of human antigen-specific cytotoxic T-cell lines, 148: 1093–1098.Google Scholar
  29. Gromet, M. A., Epstein, W. L., and Blois, M., 1978, The regressing thin malignant melanoma, Cancer 42: 2282–2292.PubMedCrossRefGoogle Scholar
  30. Habel, K., 1961, Resistance of polyoma virus immune animals to transplanted polyoma tumors, Proc. Soc. Exp. Biol. Med. 106: 722–725.PubMedGoogle Scholar
  31. Halper, J., Fu, S. M., Wang, C.-Y., Winchester, R. J., and Kunkel, H. G., 1977, Patterns of expression of human “Ia-like” antigens during terminal stages of B cell development, J. Immunol. 120: 1480–1484.Google Scholar
  32. Hellström, K. E., and Hellström, I., 1974, Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens, Adv. Immunol. 18: 209–277.PubMedCrossRefGoogle Scholar
  33. Helwig, E. B., 1963, Malignant melanoma of the skin in man, Natl. Cancer Inst. Monogr. 10: 287–295.Google Scholar
  34. Hynes, R. O., and Bye, J. M., 1974, Density and cell cycle dependence of cell surface proteins in hamster fibroblasts, Celi 3: 112–120.Google Scholar
  35. Irie, R. F., Irie, K., and Morton, D. L., 1976, A membrane antigen common to human cancer and fetal brain tissues, Cancer Res. 36: 3510–3517.PubMedGoogle Scholar
  36. Iversen, O. H., Larsen, T. E., Grude, T. H., and Magnus, K., 1975, Histological classification of malignant melanorna in relation to prognosis and cytogenesis, in: Advances in Tumor Prevention, Detection and Characterization, Vol. 13 ( W. Davis and C. Maltoni, eds. ), Copenhagen.Google Scholar
  37. Klein, G., 1975, Immunological surveillance against neoplasia, Harvey Lect. 69: 71–102.Google Scholar
  38. Koehler, G., and Milstein, C., 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature (London) 256: 495–497.CrossRefGoogle Scholar
  39. Kopf, A. W., Bart, R. S., and Rodriguez-Sains, R. S., 1977, Malignant melanoma: A review, J. Dermatol. Surg. Oncol. 3: 41–124.PubMedGoogle Scholar
  40. Koprowski, H., Love, R., and Koprowski, I., 1957, Enhancement of susceptibility to viruses in neoplastic tissues, Tex. Rep. Biol. Med. 15: 559–574.PubMedGoogle Scholar
  41. Koprowski, H., Steplewski, Z., Herlyn, D., and Herlyn, M., 1978, Study of antibodies against human melanoma produced by somatic cell hybrids, Proc. Natl. Acad. Sci. USA 75: 3405–3409.PubMedCrossRefGoogle Scholar
  42. Kurnick, J. T., Gronvik, K.-O., Kimura, A. K., Lindblom, J. K., Skoog, V. T., Sjoberg, O., and Wigzell, H., 1979, Long-term growth in vitro of human T cell blasts with maintenance of specificity and function, J. Immunol. 122: 1255–1260.PubMedGoogle Scholar
  43. Lachmann, P. J., and Sikora, K., 1978, Coupling PPD to tumor cells enhances their antigenicity in BCG-primed mice, Nature (London) 27: 463–464.CrossRefGoogle Scholar
  44. Lamm, L. U., Kissmeyer-Nielsen, F., Kjerbye, K. E., Mogensen, B., and Petersen, N. C., 1974, HLA and ABO antigens and malignant melanoma, Cancer 33:1458–1461.PubMedCrossRefGoogle Scholar
  45. Larsen, T. E., and Grude, T. H., 1978, A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I, Acta Pathol. Microbiol. Scand. Sect. A 86: 523–530.Google Scholar
  46. Lee, J. A. H., 1975, Current evidence about the causes of malignant melanoma, Prog. Clin. Cancer 6: 151–161.PubMedGoogle Scholar
  47. Lee, J. A. H., and Carter, A. P., 1970, Secular trends in mortality from malignant melanoma, J. Natl. Cancer Inst. 45: 91–97.PubMedGoogle Scholar
  48. Lemke, H., Hämmerling, G. J., Hökmann, L., and Rajewsky, K., 1978, Hybrid cell lines secreting monoclonal antibody specific for major histocompatibility antigens of the mouse, Nature (London) 271: 249–251.CrossRefGoogle Scholar
  49. Levin, D. L., and Baranovsky, A., 1976, Cancer of other specified sites, in: Cancer Patient Survival, Report No. 5 ( L. M. Axtell, A. J. Asire, and M. H. Myers, eds.), National Cancer Institute, Washington, D.C.Google Scholar
  50. Lewis, M. G., 1977, Immunology and immunotherapy of malignant melanoma, in: Malignant Melanoma of the Skin and Mucous Membranes ( G. W. Milton, ed.), pp. 102–151, Churchill Livingston, Edinburgh.Google Scholar
  51. Lewis, M. G., Hartmann, D. P., and Jerry, C. M., 1976, Antibodies and anti-antibodies in human malignancy. An expression of deranged immune regulation, Ann. N.Y. Acad. Sci. 276: 316–327.PubMedCrossRefGoogle Scholar
  52. Lindenmann, J., 1974, Viruses as immunologic adjuvants in cancer, Biochim. Biophys. Acta 355: 49–76.Google Scholar
  53. Lindenmann, J., and Klein, P. A., 1967, Viral oncolysis: Increased immunogenicity of host cell antigen associated with influenza virus, J. Exp. Med. 126: 93–108.PubMedCrossRefGoogle Scholar
  54. Livingston, P. O., Shiku, H., Bean, M. A., Pinsky, C. M., Oettgen, H. O., and Old, L. J., 1979, Cell-mediated cytotoxicity for cultured autologous melanoma cells, Int. J. Cancer 24: 34–44.PubMedCrossRefGoogle Scholar
  55. Lloyd, K. O., Travassos, L. R., Takahashi, T., and Old, L. J., 1979, Cell surface glycoproteins of human tumor cell lines: Unusual characteristics of malignant melanoma, J. Natl. Cancer Inst. 63: 623–634.PubMedGoogle Scholar
  56. Mastrangelo, M. J., Bellet, R. E., Laucius, J. F., and Berkelhammer, J., 1976, Immunotherapy of malignant melanoma: A review, in: Oncologic Medicine ( A. I. Sutrich and P. F. Engstrom, ed.), University Park Press, Baltimore.Google Scholar
  57. McCabe, R. P., Galloway, D. R., Ferrone, S., and Reisfeld, R. A., 1979, Human melanoma associated antigens (MAA): Serological and structural characteristics, in: Current Trends in Tumor Immunology ( S. Ferrone, L. Gorini, R. B. Herberman, and R. A. Reisfeld, eds.), Garland STPM Press, New York.Google Scholar
  58. McLean, D. I., Lew, R. A., Sober, A. J., Mihm, M. S., and Fitzpatrick, T. B., 1979, On the prognostic importance of white depressed areas in the primary lesion of superficial spreading melanoma, Cancer 43: 157–161.PubMedCrossRefGoogle Scholar
  59. Mishima, Y., 1965, Macromolecular changes in pigmentary disorders, Arch. Dermatol. 91: 519–557.PubMedCrossRefGoogle Scholar
  60. Mishima, Y., 1967, Melanocytic and nevocytic malignant melanomas, Cancer 20: 632–649.PubMedCrossRefGoogle Scholar
  61. Mitchison, N. A., 1970, Immunologic approach to cancer, Transplant. Proc. 2: 92–103.PubMedGoogle Scholar
  62. Morgan, D. A., Roscetti, F. W., and Gallo, R., 1976, Selective in vitro growth of T lymphocytes from normal human bone marrows, Science 193: 1007–1008.PubMedCrossRefGoogle Scholar
  63. Natori, T., Law, L. W., and Appella, E., 1977, Biological and biochemical properties of Nonidet P40-solubilized and partially purified tumor-specific antigens of the transplantation type from plasma membranes of a methylcholantrene-induced sarcoma, Cancer Res. 37: 3406–3413.PubMedGoogle Scholar
  64. Old, L. J., and Boyse, E. A., 1964, Immunology of experimental tumors, Annu. Rev. Med. 15: 167–186.PubMedCrossRefGoogle Scholar
  65. Old, L. J., and Stockert, E., 1977, Immunogenetics of cell surface antigens of mouse leukemia, Annu. Rev. Genet. 11: 127–160.PubMedCrossRefGoogle Scholar
  66. Pearson, T., Galfré, G., Ziegler, A., and Milstein, C., 1977, A myeloma hybrid producing antibody specific for an allotypic determinant on “IgD-like” molecules of the mouse, Eur. J. Immunol. 7: 684–690.PubMedCrossRefGoogle Scholar
  67. Pfreundschuh, M., Shiku, H., Takahashi, T., Ueda, R., Ransohoff, J., Oettgen, H. F., and Old, L. J., 1978, Serological analysis of cell surface antigens of malignant human brain tumors, Proc. Natl. Acad. Sci. USA 75: 5122–5126.PubMedCrossRefGoogle Scholar
  68. Pinkus, H., and Mehregan, A. H., 1976, A Guide to Dermatohistopathology, 2nd ed., pp. 441–445, AppletonCentury-Crofts, New York.Google Scholar
  69. Prager, M. D., and Baechtel, F. S., 1973, Methods for modification of cancer cells to enhance their antigenicity, Methods Cancer Res. 9: 339–400.Google Scholar
  70. Prehn, R. T., and Main, J. M., 1957, Immunity to methylcholanthrene-induced sarcomas, J. Natl. Cancer Inst. 18: 769–778.PubMedGoogle Scholar
  71. Ruoslahti, E. A., Vaheri, A., Kuusela, P., and Linder, E., 1973, Fibroblast surface antigen: A new serum glycoprotein, Biochim. Biophys. Acta 322: 352–358.PubMedCrossRefGoogle Scholar
  72. Shearer, G. M., 1974, Cell-mediated cytotoxicity to trinitrophenyl-modified syngeneic lymphocytes, Eur. J. Immunol. 4: 527.PubMedCrossRefGoogle Scholar
  73. Shiku, H., Takahashi, T., Oettgen, H. F., and Old, L. J., 1976, Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens, J. Exp. Med. 144: 873–881.PubMedCrossRefGoogle Scholar
  74. Shiku, H., Takahashi, T., Resnick, L. A., Oettgen, H. F., and Old, L. J., 1977, Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics, J. Exp. Med. 145: 784–789.PubMedCrossRefGoogle Scholar
  75. Singal, D. P., Bent, P. B., McCulloch, P. B., Blajchman, M. A., and MacLaren, R. G. C., 1974, HLA antigens in malignant melanoma, Transplantation 18: 186.PubMedCrossRefGoogle Scholar
  76. Sjögren, H. O., Hellström, I., and Klein, G., 1961, Resistance of polyoma virus immunized mice to transplantation of established polyoma tumors, Exp. Cell Res. 23: 204–208.CrossRefGoogle Scholar
  77. Stern, P. L., Willison, K. R., Lennox, E., Galfré, G., Milstein, C., Secher, D., Ziegler, A., and Springer, T., 1978, Monoclonal antibodies as probes for differentiation and tumor-associated antigens: A Forssman specificity on teratocarcinoma stem cells, Cell 14: 775–783.PubMedCrossRefGoogle Scholar
  78. Sting, G., Katz, S. I., Shevach, E., Wolff-Schriener, E., and Green, I., 1978, Detection of la antigens on Langerhans cells in guinea pig skin, J. Immunol. 120: 570–578.Google Scholar
  79. Sumner, W. C., 1953, Spontaneous regression of melanoma—Report of a case, Cancer 6: 1040–1043.PubMedCrossRefGoogle Scholar
  80. Teshima, H., Wanebo, H., Pinsky, C., and Day, N. K., 1977, Circulating immune complexes detected by 125IClq deviation test in sera of cancer patients, J. Clin. Invest. 59: 1134–1142.PubMedCrossRefGoogle Scholar
  81. Thompson, P. G., 1973, Relationship of lymphocytic infiltration to prognosis in primary malignant melanoma of skin, Pigm. Cell 1: 285–291.Google Scholar
  82. Todd, D. W., Spencer, P. W., Farrow, G. M., and Winkleman, R. K., 1996, Spontaneous regression of primary malignant melanoma with regional metastases, Proc. Mayo Clin. 41: 672–676.Google Scholar
  83. Ueda, R., Shiku, H., Pfreundschuh, M., Takahashi, T., Li, L. T. C., Whitmore, W. F., Oettgen, H. F., and Old, L. J., 1979, Cell surface antigens of human renal cancer defined by autologous typing, J. Exp. Med. 150: 564–579.PubMedCrossRefGoogle Scholar
  84. Vaheri, A., Ruoslahti, E., Westermark, B., and Pontén, J., 1976, A common cell-type specific surface antigen in cultured human glial cells and fibroblasts: Loss in malignant cells, J. Exp. Med. 143: 64–72.PubMedCrossRefGoogle Scholar
  85. Vaheri, A., Ruoslahti, E., and Mosher, D. F. (eds.), 1978, Fibroblast surface protein, Ann. N.Y. Acad. Sci., Vol. 312.Google Scholar
  86. Van Wijck, R., and C. Bouillenne, 1973, HLA antigens and susceptibility to malignant melanoma, Transplantation 16: 371.PubMedCrossRefGoogle Scholar
  87. Wallack, M. K., Steplewski, A., and Koprowski, H., 1977, A new approach in specific active immunotherapy, Cancer 39: 560–564.PubMedCrossRefGoogle Scholar
  88. Watanabe, T., Shiku, H., Li, L. T. C., Oettgen, H. F., and Old, L. J., 1980, Detection of a tumor-restricted melanoma cell surface antigen by allogeneic typing, Proc. Am. Assoc. Cancer Res. 21: 241.Google Scholar
  89. Williams, A. F., Galfré, G., and Milstein, C., 1977, Analysis of cell surfaces by xenogeneic myeloma hybrid antibodies: Differentiation antigens of rat lymphocytes, Cell 12: 663–673.PubMedCrossRefGoogle Scholar
  90. Wilson, B. S., Indiveri, F., Pellegrino, M. A., and Ferrone, S., 1979, DR (Ia-like) antigens on human melanoma cells, J. Exp. Med. 149: 658–668.PubMedCrossRefGoogle Scholar
  91. Winchester, R. J., Ross, G. D., Jarowski, C. I., Wang, C.-Y., Halper, J., and Broxmeyer, H. E., 1977, Expression of Ia-like antigen molecules on human granulocytes during early phases of differentiation, Proc. Natl. Acad. Sci. USA 74: 4012–4016.PubMedCrossRefGoogle Scholar
  92. Winchester, R. J., Wang, C.-Y., Gibofsky, A., Kunkel, H. G., Lloyd, K.O., and Old, L. J., 1978, Expression of la-like antigens on cultured human malignant melanoma cell lines, Proc. Natl. Acad. Sci. USA 75: 6235–6239.PubMedCrossRefGoogle Scholar
  93. Yeh, M.-Y., Hellström, I., Brown, J. P., Warner, G. A., Hansen, J. A., and Hellström, K. E., 1979, Cell surface antigens of human melanoma identified by monoclonal antibody, Proc. Natl. Acad. Sci. USA 76: 2927–2931.PubMedCrossRefGoogle Scholar
  94. Zinkernagel, R. M., and Doherty, P.C., 1974, Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic chomomeningitis within a syngeneic or allogeneic system, Nature (London) 248: 701–702.CrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1981

Authors and Affiliations

  • Alan N. Houghton
    • 1
  • Herbert F. Oettgen
    • 1
  • Lloyd J. Old
    • 1
  1. 1.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations